CCL1

Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs

Retrieved on: 
Thursday, July 21, 2022
Biotechnology, General Health, Pharmaceutical, Health, Shaper/Mechanist universe, Antibody, G protein-coupled receptor, CCL1, GPCR, Membrane protein, CEO, Research, University, Lists of diseases, Health, Amblyomma integrum, Cancer, University of Tokyo, ADCC, Drug development, Technology, RIKEN, Patient, Project, Immunization, Mouse, CCR8, Antigen, Vaccine, Fine chemical

February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.

Key Points: 
  • February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.
  • These antibody clones exhibit high affinity binding to human CCR8 with species cross-reactivity and good manufacturability.
  • This undoubtedly validates that LiberoThera's advanced antigen preparation technology synergizes with our RenMice KO platform to generate diverse fully human antibodies.
  • Biocytogens streamlined fully human antibody development platform greatly accelerates the translation of GPCR research.

Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs

Retrieved on: 
Thursday, July 21, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Shaper/Mechanist universe, Antibody, G protein-coupled receptor, CCL1, GPCR, Membrane protein, CEO, Research, University, Lists of diseases, Health, Amblyomma integrum, Cancer, University of Tokyo, ADCC, Drug development, Technology, RIKEN, Patient, Project, Immunization, Mouse, CCR8, Antigen, Vaccine, Fine chemical

February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.

Key Points: 
  • February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.
  • These antibody clones exhibit high affinity binding to human CCR8 with species cross-reactivity and good manufacturability.
  • This undoubtedly validates that LiberoThera's advanced antigen preparation technology synergizes with our RenMice KO platform to generate diverse fully human antibodies.
  • Biocytogens streamlined fully human antibody development platform greatly accelerates the translation of GPCR research.

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors; Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

Retrieved on: 
Thursday, October 22, 2020
Clusters of differentiation, Branches of biology, Immune system, CCR8, Regulatory T cell, Cytokines, Cell biology, CCL1

- Preclinical Proof of Concept for Company's priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)

Key Points: 
  • - Preclinical Proof of Concept for Company's priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)
    - Initiating lead optimization phase in proprietaryCCR8 Treg Program.
  • This important milestone follows Oncurious' decision to focus its development activities on a pipeline of promising novel immune-oncology targets and drug discovery projects.
  • Oncurious is now accelerating its efforts towards initiation of preclinical development of the therapeutic antibody program in early 2021.
  • Next to the anti-CCR8 program, Oncurious is focusing on 2 other programs aimed at boosting anti-tumor T cell influx and activity in immune excluded tumors.

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

Retrieved on: 
Thursday, October 22, 2020
Branches of biology, Cytokines, Immune system, Cell biology, Clusters of differentiation, Chemokine receptors, CCR8, Regulatory T cell, Chemokine, CCL1

Preclinical Proof of Concept for Companys priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)

Key Points: 
  • Preclinical Proof of Concept for Companys priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)
    Initiating lead optimization phase in proprietary CCR8 Treg Program.
  • This important milestone follows Oncurious decision to focus its development activities on a pipeline of promising novel immune-oncology targets and drug discovery projects.
  • Oncurious is now accelerating its efforts towards initiation of preclinical development of the therapeutic antibody program in early 2021.
  • Next to the anti-CCR8 program, Oncurious is focusing on 2 other programs aimed at boosting anti-tumor T cell influx and activity in immune excluded tumors.